

Sheet 1 of 2

FORM PTO 1449 (modified)		Atty. Docket No. X-16115		Serial No 10/598,302		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant ALLEN John Gordon				
		Filing Date June 9, 2008 US Nat'l Entry (if applicable)		Group 1624		
<u>U.S. PATENT DOCUMENTS</u>						
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear	
/B.C./	AA	US 2,265,890	05-05-1981	Holden, et al		
/B.C./	AB	US 5,698,766	12-16-1997	Julius, et al		
<u>FOREIGN PATENT DOCUMENTS</u>						
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/B.C./	BA	WO 93/04686 A	03-18-1993			
/B.C./	BB	WO 93/03015 A	02-18-1993			
** /B.C./	BC	WO 02/074746 A1	09-26-2002			
/B.C./	BD	WO 03/006466	01-23-2003			
/B.C./	BE	EP 285 287 A2	05.10.1988			
<u>NON PATENT LITERATURE DOCUMENTS</u>						
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.				T ⁶
/B.C./	CA	Kilpatrick, et al., "The alpha 2-adrenoreceptor antagonist SK & F 104078 has high affinity for 5-HT _{1A} and 5-HT ₂ receptors European Journal of Pharmacology", 166(2) 315-18 Coden 1989				
/B.C./	CB	DATABASE WPI- Section Ch, Week 200274, Derwent Publications LTD., London, GB; Class B02, AN 2002-691852 XP002328506 2002				
/B.C./	CC	Teacott, et al, "Eating disorder and epilepsy in mice lacking 5-HT _{2C} serotonin receptors" Nature, Vol 374, 542-546, 1995				
/B.C./	CD	Upton, et al, "Studies on the role of 5-HT _{2C} and 5-HT _{2B} receptors in regulating generalized seizure threshold in rodents" European J. O Pharmacology, 359, 33-40 (1998)				

** structures only

Examiner Signature	/Brenda Coleman/	Date Considered	09/18/2010
-----------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached Burden Hours Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

FORM PTO 1449 (modified)		Atty. Docket No. X-16115	Serial No 10/598,302
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant ALLEN John Gordon	
		Filing Date June 9, 2008 US Nat'l Entry (if applicable)	Group 1624
<u>NON PATENT LITERATURE DOCUMENTS</u>			
/B.C./	CE	Vickers, et al, "Oral administration of the 5-HT _{2c} receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia" <u>Psychopharmacology</u> , 167: 274-280 (2003)	
/B.C./	CF	Martin, et al, "Influence of the 5-HT _{2c} receptor antagonist, SB-242084, in tests of anxiety" <u>Pharmacology Biochemistry and Behavior</u> : 71:615-625 (2002)	
/B.C./	CG	Chou-Green, et al, "Compulsive behavior in the 5-HT _{2c} receptor knockout mouse" <u>Physiology & Behavior</u> , 78, 641-649 (2003)	
/B.C./	CH	Frank, et al, "Sleep and Sleep Homeostasis in Mice Lacking the 5-HT _{2c} Receptor" <u>Neuropsychopharmacology</u> , 27:5, 869-873 (2002)	
/B.C./	CI	Leysen, et al, "Ligands for the 5-HT _{2c} receptor as potential Antidepressants and Anxiolytics" <u>Trends In Drug Research II</u> , 49-61 (1998)	
/B.C./	CJ	Fitzgerald, et al., "Chapter 3: 5-HT _{2c} Receptor Modulators : Progress in Development of New CNS Medicines: <u>Annual Reports in Medicinal Chemistry</u> 37, 21, 2002	

Examiner Signature	/Brenda Coleman/	Date Considered	09/18/2010
-----------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached Burden Hours Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: ALLEN John Gordon

For: 6-SUBSTITUTED2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES

AS 5-HT_{2C} RECEPTOR AGONISTS

Docket No.: X16115

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner, together with copies of PTO-892 forms submitted to Applicants by Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/ R. Craig Tucker/
Attorney for Applicants
Registration No. 45,165
Phone: 317-433-9829

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
July 18, 2006